BEYOND Follow-up: Betaferon®/Betaseron® Efficacy Yielding Outcomes of a New Dose

NCT00459667 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1420

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Sclerosis, Relapsing-Remitting

Interventions

DRUG: Interferon beta-1b (Betaseron, BAY86-5046)
DRUG: Interferon beta-1b (Betaseron, BAY86-5046)
DRUG: Interferon beta-1b (Betaseron, BAY86-5046)

Sponsor

Bayer